Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
BMC Genomics|July 3, 2023
Gene expression profiling unveils the temporal dynamics of CIGB-300-regulated transcriptome in AML cell linesDania Vázquez-Blomquist, Ailyn C Ramón, Mauro Rosales, et al.Journal of Proteomics|August 4, 2024
"Phosphoproteomic quantification based on phosphopeptide intensity or occupancy? An evaluation based on casein kinase 2 downstream effects"Arielis Rodríguez-Ulloa, Mauro Rosales, Yassel Ramos, et al.Frontiers in Molecular Biosciences|April 1, 2022
CIGB-300-Regulated Proteome Reveals Common and Tailored Response Patterns of AML Cells to CK2 InhibitionMauro Rosales, Arielis Rodríguez-Ulloa, George V Pérez, et al.Cells|February 10, 2021
Phosphoproteomic Landscape of AML Cells Treated with the ATP-Competitive CK2 Inhibitor CX-4945Mauro Rosales, Arielis Rodríguez-Ulloa, Vladimir Besada, et al.Viruses|March 26, 2022
Targeting of Protein Kinase CK2 Elicits Antiviral Activity on Bovine Coronavirus InfectionAilyn C Ramón, George V Pérez, Evelin Caballero, et al.Biomedicines|January 21, 2023
CIGB-300 Anticancer Peptide Differentially Interacts with CK2 Subunits and Regulates Specific Signaling Mediators in a Highly Sensitive Large Cell Lung Carcinoma Cell ModelGeorge V Pérez, Mauro Rosales, Ailyn C Ramón, et al.Biomedicines|August 6, 2021
Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300Mauro Rosales, George V Pérez, Ailyn C Ramón, et al.ACS Pharmacology & Translational Science|February 22, 2021
Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical TrialLeticia R Cruz, Idania Baladrón, Aliusha Rittoles, et al.Pageof 1